Ignition Capital

Ignition Capital is a private equity firm founded in 2008 and headquartered in Bellevue, Washington, with additional offices in Seattle, Palo Alto, Beijing, Shanghai, and Hong Kong. The firm specializes in buyouts, mid to late-stage investments, and turnaround opportunities, focusing on providing growth capital. Ignition Capital targets a diverse array of sectors, including technology and communications, consumer services, and healthcare. Within healthcare, it invests in primary care facilities, biotechnology advancements, and pharmaceuticals. In the consumer sector, it backs companies leveraging technology in education, retail, e-commerce, and other services. The firm is an active investor, typically seeking a controlling or leading interest in its investments, and engages in co-investments. Ignition Capital operates primarily in the United States and China, offering both investment and operational support to its portfolio companies.

Jon Anderson

Co-Founder and Managing Director

John Zagula

Co-Founding Partner and Managing Director

8 past transactions

PaxVax

Private Equity Round in 2015
PaxVax Corporation is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines targeting various infectious diseases. Founded in 2006 and headquartered in Redwood City, California, PaxVax has pioneered a proprietary oral vaccine technology based on adenovirus, which addresses the logistical challenges of traditional injectable vaccines, such as cold storage and the need for medical personnel for administration. The company’s vaccine portfolio includes products for cholera, typhoid fever, hepatitis A, avian influenza, anthrax, and components for HIV, among others. Additionally, PaxVax is actively engaged in developing vaccines for malaria, dengue, rabies, and herpes simplex virus. With research and development facilities in San Diego, California, and Thörishaus, Switzerland, PaxVax aims to provide innovative solutions for travelers and biodefense, both in the United States and internationally. It operates as a subsidiary of Emergent BioSolutions, Inc.

YPX Cayman Holdings

Series D in 2014
YPX Cayman Holdings Co., Ltd., established in Shanghai, China in 2010, is a restaurant management company operating primarily in the Chinese market. The company's core business involves managing a chain of restaurants under its own brand, Cloud9 吞云小莳, specializing in Taiwanese casual dining and snacks. Additionally, YPX Cayman Holdings aims to introduce international food brands into China through franchising or partnerships, with an ambition to expand its total store count to approximately 1,500 by the year 2020, encompassing multiple brands.

PaxVax

Series B in 2014
PaxVax Corporation is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines targeting various infectious diseases. Founded in 2006 and headquartered in Redwood City, California, PaxVax has pioneered a proprietary oral vaccine technology based on adenovirus, which addresses the logistical challenges of traditional injectable vaccines, such as cold storage and the need for medical personnel for administration. The company’s vaccine portfolio includes products for cholera, typhoid fever, hepatitis A, avian influenza, anthrax, and components for HIV, among others. Additionally, PaxVax is actively engaged in developing vaccines for malaria, dengue, rabies, and herpes simplex virus. With research and development facilities in San Diego, California, and Thörishaus, Switzerland, PaxVax aims to provide innovative solutions for travelers and biodefense, both in the United States and internationally. It operates as a subsidiary of Emergent BioSolutions, Inc.

PreViser

Venture Round in 2013
PreViser Corporation is a developer of dental risk and periodontal disease analysis software solutions, founded in 2002 and based in Concord, New Hampshire. The company offers PreViser, an analytic software tool that allows dental professionals—including dentists, hygienists, periodontists, and orthodontists—to measure, understand, and communicate their patients' oral health risks and disease levels through numeric scores. This software also supports academic institutions in teaching students how to quantitatively assess risk and disease management in clinical dentistry. Additionally, PreViser operates mydentalscore.com, a platform that educates employers and dental insurers, helping consumers understand the significance of good oral health while enabling patients to generate their own oral disease risk and health scores based on personal information. PreViser enhances the efficiency of dental care through its web-enabled diagnostic and treatment planning decision support software. As of February 2016, PreViser operates as a subsidiary of Red Tree Holdings, Inc.

YPX Cayman Holdings

Series C in 2012
YPX Cayman Holdings Co., Ltd., established in Shanghai, China in 2010, is a restaurant management company operating primarily in the Chinese market. The company's core business involves managing a chain of restaurants under its own brand, Cloud9 吞云小莳, specializing in Taiwanese casual dining and snacks. Additionally, YPX Cayman Holdings aims to introduce international food brands into China through franchising or partnerships, with an ambition to expand its total store count to approximately 1,500 by the year 2020, encompassing multiple brands.

Tier 3

Series B in 2012
Tier 3 is a company that specializes in delivering enterprise-class cloud services and software designed to enhance business agility. Their offerings include virtual private cloud services, which integrate both infrastructure as a service (IaaS) and platform as a service (PaaS) into a unified platform. This Tier 3 Cloud solution aims to improve IT operational efficiency and flexibility through advanced cloud orchestration and management capabilities. The company's services are tailored for global enterprises and service providers, supporting a wide range of business applications from development to production environments, including mission-critical applications.

Spoken Communications

Series B in 2012
Spoken Communications specializes in providing a cloud-based contact center platform designed to enhance performance and customer outcomes. Their flagship product, Spoken ConversationCenter, is an AI-enabled solution that manages and analyzes various digital conversations, including voice interactions through their patented TrueMeaning technology. This platform allows service providers to efficiently meet the evolving demands of modern consumers by optimizing service delivery costs through the use of AI and Big Data. Spoken's system supports omnichannel communications, intelligent skills-based routing, and real-time transcription, which help improve agent performance and customer satisfaction. By enabling continuous improvement in contact center operations, Spoken Communications aims to redefine the customer experience while reducing the need for costly agent transfers.

Spoken Communications

Series A in 2010
Spoken Communications specializes in providing a cloud-based contact center platform designed to enhance performance and customer outcomes. Their flagship product, Spoken ConversationCenter, is an AI-enabled solution that manages and analyzes various digital conversations, including voice interactions through their patented TrueMeaning technology. This platform allows service providers to efficiently meet the evolving demands of modern consumers by optimizing service delivery costs through the use of AI and Big Data. Spoken's system supports omnichannel communications, intelligent skills-based routing, and real-time transcription, which help improve agent performance and customer satisfaction. By enabling continuous improvement in contact center operations, Spoken Communications aims to redefine the customer experience while reducing the need for costly agent transfers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.